The FDA approved clinical trials of a compound for Alzheimer's disease and schizophrenia by the Vanderbilt Center for Neuroscience Drug Discovery. The academic center is taking a new step into clinical studies as pharmaceutical companies are reducing their backing of neuroscience research.
The FDA granted Merck & Co. priority review status for Keytruda as a first-line treatment for advanced non-small cell lung cancer with tumors that express PD-L1. Keytruda is approved to treat melanoma and is under study against more than 30 forms of cancer.
Epizyme's tazemetostat has been granted fast-track designation by the FDA as a treatment for relapsed or refractory diffuse large B-cell lymphoma in patients with an EZH2-activating mutation. The drug is also being developed as a treatment for non-Hodgkin lymphoma and some genetically defined solid tumors.
Lupin received an FDA establishment inspection report allowing it to resume drug production for the US market at its Goa, India, plant. The notification confirmed the resolution of issues raised by FDA inspectors in March.
Embrace Disruptive Innovation Traditional business is constantly being impacted by overwhelming and sudden shifts in the marketplace. This new normal is "disruptive innovation". Read this white paper to learn what disruptive innovation is and how your company can use cloud ERP to stay in the game. Download the white paper >
A marketing authorization application has been submitted to the European Medicines Agency by GlaxoSmithKline for its shingles vaccine Shingrix. The filing was backed by late-stage study data that demonstrated the drug's ability to reduce the overall incidence of postherpetic neuralgia in addition to reducing the incidence of shingles.
Janssen has filed a marketing authorization application with the European Medicines Agency for guselkumab as a treatment for moderate to severe plaque psoriasis in adults. The submission was supported by data from four studies that evaluated the safety and efficacy of the drug when administered by subcutaneous injection.
Takeda Pharmaceutical's Ninlaro, or ixazomib, has received conditional approval from the European Commission for use along with lenalidomide and dexamethasone as a treatment for multiple myeloma in adult patients who have received at least one previous therapy. Late-stage study data showed the combination treatment improved median progression-free survival compared with only dexamethasone or lenalidomide.
A total of 3,588 cases of Harvest Snap Black Pepper snap pea crisps are being recalled by Calbee because they may actually contain Harvest Snap Wasabi Ranch snap pea crisps that contain milk not declared on the label. The products being recalled are packed in 3.3-ounce bags, have the lot number MAR 31 17 0141 S and were sold Oct. 3-4 in Florida's Publix Super Market stores.
The FDA has given Dilon Diagnostics and GE Healthcare approval for a molecular breast imaging localization accessory for breast biopsy, which is intended to complement GE's Discovery NM750b system. The accessory, designed to provide guidance for interventional applications, uses information from stereotactic pairs of two-dimensional images to precisely locate breast lesions in three dimensions.
An urgent field safety notice has been issued by Medtronic concerning three fires connected to its Formula hemodialysis machines, two of which were caused by issues with the device's battery charge board. The company said it is developing a permanent solution to correct the issue and recommended in the meantime that the battery charge board be disconnected.
A comprehensive statement of the law -- essential to every office, library, and classroom -- this resource includes valuable information on the FDA's administrative and enforcement authority, and also contains the latest information on new statutes, regulations, guidances and case law. Learn more.
The 2017 FDLI Annual Conference will cover the latest in legal, regulatory and policy issues spanning the broad range of the FDA's authority by bringing together experts from the federal government, industry, the private bar, non-profit, patient and consumer advocates, consulting organizations and academia. Learn more.